The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
List view / Grid view
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
The European Commission (EC) granted marketing authorisation for Darzalex in combination with bortezomib, thalidomide and dexamethasone (VTd) for multiple myeloma patients.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
17 May 2017 | By Dr Catherine Taylor, Haematology Therapeutic Area Lead, Janssen EMEA
We caught up with Janssen's Dr Catherine Taylor to talk monoclonal antibodies, the rise of immuno-oncology and treating multiple myeloma...